Vectormune FP ILT

Country: European Union

Language: Bulgarian

Source: EMA (European Medicines Agency)

Buy It Now

Patient Information leaflet Patient Information leaflet (PIL)
01-01-1970
Summary of Product characteristics Summary of Product characteristics (SPC)
01-01-1970
Public Assessment Report Public Assessment Report (PAR)
01-01-1970

Active ingredient:

recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus, live

Available from:

CEVA-Phylaxia Co. Ltd.

INN (International Name):

Fowlpox and avian infectious laryngotracheitis vaccine (live, recombinant)

Therapeutic group:

Пиле

Therapeutic indications:

For active immunisation of chickens from 8 weeks of age in order to reduce the skin lesions due to fowlpox and to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis.

Authorization status:

упълномощен

Authorization date:

2020-12-09

Patient Information leaflet

                                19
B. ЛИСТОВКА
20
ЛИСТОВКА:
VECTORMUNE FP ILT
ЛИОФИЛИЗАТ И РАЗТВОРИТЕЛ ЗА
ИНЖЕКЦИОННА СУСПЕНЗИЯ ЗА ПИЛЕТА
1.
ИМЕ И ПОСТОЯНEН АДРЕС НА ПРИТЕЖАТЕЛЯ
НА ЛИЦЕНЗА ЗА УПОТРЕБА
И НА ПРОИЗВОДИТЕЛЯ, АКО ТЕ СА РАЗЛИЧНИ
Притежател на лиценза за употреба и
производител, отговорен за
освобождаване на партидата:
Ceva- Phylaxia Co. Ltd.
1107 Budapest
Szállás u 5.
Hungary
2.
НАИМЕНОВАНИЕ НА
ВЕТЕРИНАРНОМЕДИЦИНСКИЯ ПРОДУКТ
Vectormune FP ILT лиофилизат и разтворител за
инжекционна суспензия за пилета
3.
СЪДЪРЖАНИЕ НА АКТИВНИТЕ СУБСТАНЦИИ И
ЕКСЦИПИЕНТИТЕ
Всяка доза (0.01 ml) съдържа:
АКТИВНИ СУБСТАНЦИИ:
Жив рекомбинантен вирус на шарката по
птиците, експресиращ мембранния фюжън
протеин и
инкапсидиращия протеин на вируса на
инфекциозния ларинготрахеит по
птиците (rFP-LT)
2.7 до 4.5 log10 TCID50*
* 50% Tissue Culture Infective Dose (тъканно
културална инфекциозна доза)
Лиофилизат: розов или бежов.
Разтворител: бистра синя течност.
4.
ТЕРАПЕВТИЧНИ ПОКАЗАНИЯ
За
активна
имунизация
на
пилета
на
възраст
от
8
седмици
за
намаляване
на
кожните
лезии,
предизвикани от вируса на шарката, за
намаляване на клиничните признаци и
трахеалните лезии,
предизвикани от вируса на
инфекциозния ларинготрахеит.
Начало на им
                                
                                Read the complete document

Summary of Product characteristics

                                1
ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
2
1.
НАИМЕНОВАНИЕ НА
ВЕТЕРИНАРНОМЕДИЦИНСКИЯ ПРОДУКТ
Vectormune FP ILT лиофилизат и разтворител за
инжекционна суспензия за пилета
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
Всяка доза (0.01 ml) съдържа:
АКТИВНИ СУБСТАНЦИИ:
Жив рекомбинантен вирус на шарката по
птиците, експресиращ мембранния фюжън
протеин и
инкапсидиращия протеин на вируса на
инфекциозния ларинготрахеит по
птиците (rFP-LT)
2.7 до 4.5 log10 TCID50*
* 50% Tissue Culture Infective Dose (тъканно
културална инфекциозна доза)
ЕКСЦИПИЕНТИ:
За пълния списък на ексципиентите, виж
т. 6.1.
3.
ФАРМАЦЕВТИЧНА ФОРМА
Лиофилизат и разтворител за
инжекционна суспензия.
Лиофилизат: розов или бежов.
Разтворител: бистра синя течност.
4.
КЛИНИЧНИ ДАННИ
4.1
ВИДОВЕ ЖИВОТНИ, ЗА КОИТО Е
ПРЕДНАЗНАЧЕН ВМП
Пилета.
4.2
ТЕРАПЕВТИЧНИ ПОКАЗАНИЯ, ОПРЕДЕЛЕНИ ЗА
ОТДЕЛНИТЕ ВИДОВЕ ЖИВОТНИ
За
активна
имунизация
на
пилета
на
възраст
от
8
седмици
за
намаляване
на
кожните
лезии,
предизвикани от вируса на шарката и за
намаляване на клиничните признаци и
трахеалните лезии,
предизвикани от вируса на
инфекциозния ларинготрахеит.
Начало на имунитета:
За шарка и инфекциозен ларинготрахеит
                                
                                Read the complete document

Similar products

Active ingredient recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus, live

recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus, live

Marketed by CEVA-Phylaxia Co. Ltd.

CEVA-Phylaxia Co. Ltd.

INN (International Name) Fowlpox and avian infectious laryngotracheitis vaccine (live, recombinant)

Fowlpox and avian infectious laryngotracheitis vaccine (live, recombinant)

Documents in other languages

Patient Information leaflet Patient Information leaflet Spanish 01-01-1970
Summary of Product characteristics Summary of Product characteristics Spanish 01-01-1970
Public Assessment Report Public Assessment Report Spanish 01-01-1970
Patient Information leaflet Patient Information leaflet Czech 01-01-1970
Summary of Product characteristics Summary of Product characteristics Czech 01-01-1970
Public Assessment Report Public Assessment Report Czech 01-01-1970
Patient Information leaflet Patient Information leaflet Danish 01-01-1970
Summary of Product characteristics Summary of Product characteristics Danish 01-01-1970
Public Assessment Report Public Assessment Report Danish 01-01-1970
Patient Information leaflet Patient Information leaflet German 01-01-1970
Summary of Product characteristics Summary of Product characteristics German 01-01-1970
Public Assessment Report Public Assessment Report German 01-01-1970
Patient Information leaflet Patient Information leaflet Estonian 01-01-1970
Summary of Product characteristics Summary of Product characteristics Estonian 01-01-1970
Public Assessment Report Public Assessment Report Estonian 01-01-1970
Patient Information leaflet Patient Information leaflet Greek 01-01-1970
Summary of Product characteristics Summary of Product characteristics Greek 01-01-1970
Public Assessment Report Public Assessment Report Greek 01-01-1970
Patient Information leaflet Patient Information leaflet English 01-01-1970
Summary of Product characteristics Summary of Product characteristics English 01-01-1970
Public Assessment Report Public Assessment Report English 01-01-1970
Patient Information leaflet Patient Information leaflet French 01-01-1970
Summary of Product characteristics Summary of Product characteristics French 01-01-1970
Public Assessment Report Public Assessment Report French 01-01-1970
Patient Information leaflet Patient Information leaflet Italian 01-01-1970
Summary of Product characteristics Summary of Product characteristics Italian 01-01-1970
Public Assessment Report Public Assessment Report Italian 01-01-1970
Patient Information leaflet Patient Information leaflet Latvian 01-01-1970
Summary of Product characteristics Summary of Product characteristics Latvian 01-01-1970
Public Assessment Report Public Assessment Report Latvian 01-01-1970
Patient Information leaflet Patient Information leaflet Lithuanian 01-01-1970
Summary of Product characteristics Summary of Product characteristics Lithuanian 01-01-1970
Public Assessment Report Public Assessment Report Lithuanian 01-01-1970
Patient Information leaflet Patient Information leaflet Hungarian 01-01-1970
Summary of Product characteristics Summary of Product characteristics Hungarian 01-01-1970
Public Assessment Report Public Assessment Report Hungarian 01-01-1970
Patient Information leaflet Patient Information leaflet Maltese 01-01-1970
Summary of Product characteristics Summary of Product characteristics Maltese 01-01-1970
Public Assessment Report Public Assessment Report Maltese 01-01-1970
Patient Information leaflet Patient Information leaflet Dutch 01-01-1970
Summary of Product characteristics Summary of Product characteristics Dutch 01-01-1970
Public Assessment Report Public Assessment Report Dutch 01-01-1970
Patient Information leaflet Patient Information leaflet Polish 01-01-1970
Summary of Product characteristics Summary of Product characteristics Polish 01-01-1970
Public Assessment Report Public Assessment Report Polish 01-01-1970
Patient Information leaflet Patient Information leaflet Portuguese 01-01-1970
Summary of Product characteristics Summary of Product characteristics Portuguese 01-01-1970
Public Assessment Report Public Assessment Report Portuguese 01-01-1970
Patient Information leaflet Patient Information leaflet Romanian 01-01-1970
Summary of Product characteristics Summary of Product characteristics Romanian 01-01-1970
Public Assessment Report Public Assessment Report Romanian 01-01-1970
Patient Information leaflet Patient Information leaflet Slovak 01-01-1970
Summary of Product characteristics Summary of Product characteristics Slovak 01-01-1970
Public Assessment Report Public Assessment Report Slovak 01-01-1970
Patient Information leaflet Patient Information leaflet Slovenian 01-01-1970
Summary of Product characteristics Summary of Product characteristics Slovenian 01-01-1970
Public Assessment Report Public Assessment Report Slovenian 01-01-1970
Patient Information leaflet Patient Information leaflet Finnish 01-01-1970
Summary of Product characteristics Summary of Product characteristics Finnish 01-01-1970
Public Assessment Report Public Assessment Report Finnish 01-01-1970
Patient Information leaflet Patient Information leaflet Swedish 01-01-1970
Summary of Product characteristics Summary of Product characteristics Swedish 01-01-1970
Public Assessment Report Public Assessment Report Swedish 01-01-1970
Patient Information leaflet Patient Information leaflet Norwegian 01-01-1970
Summary of Product characteristics Summary of Product characteristics Norwegian 01-01-1970
Patient Information leaflet Patient Information leaflet Icelandic 01-01-1970
Summary of Product characteristics Summary of Product characteristics Icelandic 01-01-1970
Patient Information leaflet Patient Information leaflet Croatian 01-01-1970
Summary of Product characteristics Summary of Product characteristics Croatian 01-01-1970
Public Assessment Report Public Assessment Report Croatian 01-01-1970

Search alerts related to this product

Alerts Vectormune ILT recombinant fowlpox virus expressing and avian infectious laryngotracheitis

Vectormune ILT recombinant fowlpox virus expressing and avian infectious laryngotracheitis

View documents history

Documents history Documents history

Vectormune FP ILT